Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals, or no treatment: a retrospective cohort study

被引：2

作者：

Drysdale, Myriam ^{[1
]}

Tibble, Holly ^{[2
]}

Patel, Vishal ^{[1
]}

Gibbons, Daniel C. ^{[1
]}

Lloyd, Emily J. ^{[1
]}

Kerr, William ^{[3
]}

Macdonald, Calum ^{[2
]}

Birch, Helen J. ^{[1
]}

Sheikh, Aziz ^{[2
]}

机构：

[1] GSK House, Value Evidence & Outcomes, 980 Great West Rd, Brentford TW8 9GS, Middlesex, England

[2] Univ Edinburgh, Usher Inst, Edinburgh, Scotland

[3] GSK, Global Med Affairs, Brentford, England

来源：

BMC INFECTIOUS DISEASES | 2024年 / 24卷 / 01期

关键词：

COVID-19; Sotrovimab; Molnupiravir; Nirmatrelvir/ritonavir; Omicron BA.1; Omicron BA.2; Omicron BA.5; Oral antivirals; Monoclonal antibody;

D O I：

10.1186/s12879-024-09576-7

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Background The clinical benefit of coronavirus disease 2019 (COVID-19) treatments against new circulating variants remains unclear. We sought to describe characteristics and clinical outcomes of highest risk patients with COVID-19 receiving early COVID-19 treatments in Scotland. Methods Retrospective cohort study of non-hospitalized patients diagnosed with COVID-19 from December 1, 2021-October 25, 2022, using Scottish administrative health data. We included adult patients who met >= 1 of the National Health Service highest risk criteria for early COVID-19 treatment and received outpatient treatment with sotrovimab, nirmatrelvir/ritonavir or molnupiravir, or no early COVID-19 treatment. Index date was defined as the earliest of COVID-19 diagnosis or early COVID-19 treatment. Baseline characteristics and acute clinical outcomes in the 28 days following index were reported. Values of <= 5 were suppressed. Results In total, 2548 patients were included (492: sotrovimab, 276: nirmatrelvir/ritonavir, 71: molnupiravir, and 1709: eligible highest risk untreated). Patients aged >= 75 years accounted for 6.9% (n = 34/492), 21.0% (n = 58/276), 16.9% (n = 12/71) and 13.2% (n = 225/1709) of the cohorts, respectively. Advanced renal disease was reported in 6.7% (n = 33/492) of sotrovimab-treated and 4.7% (n = 81/1709) of untreated patients, and <= 5 nirmatrelvir/ritonavir-treated and molnupiravir-treated patients. All-cause hospitalizations were experienced by 5.3% (n = 25/476) of sotrovimab-treated patients, 6.9% (n = 12/175) of nirmatrelvir/ritonavir-treated patients, <= 5 (suppressed number) molnupiravir-treated patients and 13.3% (n = 216/1622) of untreated patients. There were no deaths in the treated cohorts; mortality was 4.3% (n = 70/1622) among untreated patients. Conclusions Sotrovimab was often used by patients who were aged < 75 years. Among patients receiving early COVID-19 treatment, proportions of 28-day all-cause hospitalization and death were low.

引用

页数：10